CDK4 and neoplasm: CDK4/6 inhibitors, approved by the FDA in 2015 for the first-line treatment of HR(+)/HER2 (–) advanced breast cancer (15), primarily inhibit the phosphorylation of the retinoblastoma gene (Rb), blocking the G1 phase of the cell cycle in tumor cells (16).